Mazindol Stats & Data

Mechanism: primarily inhibits norepinephrine and dopamine transporters; much weaker serotonin effects relative to NET/DAT, which guides interaction risk (e.g., less serotonergic liability than amphetamines). Start with the low end of dosing, particularly in stimulant-naïve users, and avoid redosing because the 10–13 h half-life produces prolonged cardiovascular stimulation. Baseline and on-day checks of blood pressure and heart rate reduce risk; discontinue and seek care with chest pain, severe headache, shortness of breath, or palpitations. Avoid use with MAOIs or within 14 days of MAOI exposure due to risk of hypertensive crisis; this is a general rule for sympathomimetics. Avoid combining with other stimulants (including OTC decongestants) to limit additive tachycardia and hypertension. In those on SNRIs or other noradrenergic agents (atomoxetine, bupropion, many TCAs), additive increases in BP/HR and anxiety are more likely; if co-prescribed medically, dose conservatively and monitor vitals. For SSRI users, serotonin toxicity risk appears lower than with serotonergic stimulants, but agitation, anxiety, and insomnia may be amplified—treat as a caution combination. Dose early in the day; avoid late-afternoon/evening dosing to minimize sleep disruption. Take with or without food; taking 1 hour before meals is common in labels, and food may reduce GI upset. Hepatic metabolism suggests added caution with significant liver disease. Typical adverse effects include insomnia, dry mouth, palpitations, anxiety, and decreased appetite; severe events are uncommon at therapeutic doses but have included arrhythmias in isolated cases. Stay hydrated and maintain nutrition given strong appetite suppression; prolonged caloric deficit can worsen side effects.